buerger disease hyperhomocysteinemia vascular occlusions Buerger’s disease atherosclerosis homocysteine folic acid
Conditions
Interventions
folic acid therapy for 12 weeks in 3 groups to measure the effect on decrease of homocystein
Experimental Drug
folic acid therapy for 12 weeks
Sponsors
none
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: buerger disease patients have Shionoya criteria and atherosclerosis was proved by angiography
Exclusion criteria
Exclusion criteria: The exclusion criteria were age under 18 years; alcohol consumption; recent use of methotrexate, trimethoprim, phenytoin, carbamazepine, or theophylline; and underlying diseases such as malignancy, systemic diseases, systemic lupus erythematosus, rheumatoid arthritis, and hypothyroidism. To minimize the possible interactions of confounding factors, vitamin B12, 1000 U/w, was intravenously administered to all of the participants one week prior to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| homocysteine 04/02/2011 Axis® Homocysteine Enzyme Immunoassay (EIA) kit (UK). | — |
Secondary
| Measure | Time frame |
|---|---|
| homocysteine 04/02/2011 Axis® Homocysteine Enzyme Immunoassay (EIA) kit (UK). | — |
Countries
iran
Contacts
Public Contacthassan ravari
professor
Outcome results
None listed